Impact BioMedical Closes Zoar Merger; IBO Delisted, PubCo Trades as ZOAR
Summary
Impact BioMedical completed its merger with Zoar Limited on November 17, 2026, converting Impact shares into 8,640,000 PubCo ordinary shares (about 4.80% of the combined company) after a 1-for-12.62 reverse split. IBO is being delisted from NYSE American, with PubCo shares expected to trade as 'ZOAR' starting November 18, 2026.
Key Events · M&A and Partnerships · IBO
-
Zoar Merger Closes
On November 17, 2026, Merger Sub merged into Impact and PubCo acquired all Zoar ordinary shares, completing the business combination approved by stockholders on November 13, 2026.
-
Share Consideration Allocated
Impact holders received 8,640,000 PubCo ordinary shares, about 4.80% of PubCo at Closing, after a 1-for-12.62 reverse split; the Zoar Shareholder received 167,976,000 shares, about 94.02%.
-
No Cash Consideration
PubCo funded the merger consideration entirely through issuance of PubCo ordinary shares and paid no cash consideration.
-
IBO Delisting and ZOAR Listing
Impact requested NYSE American suspend trading of IBO before the open on November 18, 2026 and delist it via Form 25; PubCo shares are expected to trade under 'ZOAR' on November 18, 2026.
Analysis · IBO · Life Sciences
The Zoar Limited business combination closed on November 17, 2026, ending Impact BioMedical as a standalone NYSE American issuer. Impact stockholders received 8,640,000 PubCo ordinary shares, about 4.80% of the combined company, after a 1-for-12.62 reverse split, while Zoar's sole shareholder Kanans Visvanats holds roughly 94.02% and controls the voting power. No cash changed hands: the consideration was paid entirely in PubCo shares. IBO common stock stops trading and is being delisted, with PubCo shares expected to begin trading under 'ZOAR' on November 18, 2026. The entire Impact board, CFO and COO resigned, and a new PubCo board and executive team took over. For existing holders, the thesis is now the Zoar business and a tightly controlled share register, not Impact's prior going-concern profile.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IBO was trading at $5.25 on NYSE in the Life Sciences sector, with a market capitalization of approximately $53.3M. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.